Industry Verticals »

All Categories

Insights »

About TMR »

Erectile Dysfunction (ED) Drugs Market

Erectile Dysfunction (ED) Drugs Market (Drug: Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Erectile Dysfunction (ED) Drugs Market Outlook 2028

  • The global erectile dysfunction drugs market was valued at US$ 3.4 Bn in 2020
  • It is estimated to incur value growth at a CAGR of -3.1% from 2021 to 2028
  • The global erectile dysfunction (ED) drugs industry is expected to reach the value of US$ 2.5 Bn by the end of 2028

Erectile Dysfunction Drugs Market: Overview

  • According to Transparency Market Research’s latest report on the global market for erectile dysfunction (ED) drugs for the historical period 2017–2019 and forecast period 2021–2028, some factors that drive the global market for erectile dysfunction (ED) drugs include the adoption of a sedentary lifestyle and its associated stress, rising geriatric population, and comorbidity between erectile dysfunction and heart disease and diabetes

Increase in Awareness and Patient Education: Key Driver

  • Educating patients on the appropriate use of erectile dysfunction drugs can be effective through initial education and focusing on the method of administration of drugs. For instance, sildenafil and vardenafil should be taken an hour before intercourse, and food and alcohol intake should be avoided, thereby maintaining the speed and extent of drug absorption. Both drugs are active for four to six hours. Tadalafil has the advantage of long duration of action i.e., for up to 36 hours. The absorption of tadalafil is unaffected by food and alcohol and the intake of tadalafil is advised several hours before sexual activity. Moreover, adequate sexual stimulation, ideally with a partner, is required.
  • Promotional and awareness campaigns for ED drugs should be extensively conducted to help minimize the stigma of impotence by bringing it out onto open discussion forums
  • Companies are working on educating the general population and people at risk, and advocating lifestyle changes
  • Pharmacists assess the needs of patients and identify drug problems to manage medication therapy

Narrowing of Insurance Coverage for Erectile Dysfunction Treatment

  • Development of pharmaceutical and branded drugs incur large investments and longer duration of time in R&D activities and making them available to the patients for the treatment
  • Modifications in healthcare insurance coverage can significantly affect the drug market. If an insurance program changes its policies and removes coverage for a certain treatment, sales of related drugs are likely to decrease. In general, insurance programs are more likely to cover essential expenses, such as heart disease medication, and are less likely to cover nonessential expenses, such as cosmetic surgery. The type of treatment prescribed for erectile dysfunction decides the possibility of insurance coverage. A person with a documented medical condition responsible for the cause of erectile dysfunction could incur insurance benefits. However, sex therapies and medications that have not been approved by the FDA have not been covered under insurance.
  • Due to its low dynamic nature, the trend of switching to new drugs or automatic substitution is not prevalent in the erectile dysfunction drugs market, thereby creating further hurdles for players willing to enter the market

Erectile Dysfunction (ED) Drugs Industry: Competition Landscape

  • This report profiles major players in the global ED drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global erectile dysfunction drugs market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global erectile dysfunction (ED) drugs market are
    • Pfizer, Inc.
    • Dong-A ST Co., Ltd.
    • Eli Lilly and Company
    • Bayer AG
    • Vivus, Inc.
    • Teva Pharmaceutical Industries Ltd.
  • Manufacturers are launching new products in the international market to tap the unmet needs of erectile dysfunction
  • Other prominent players operating in the global market include SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Futura Medical plc.

Erectile Dysfunction (ED) Drugs Market: Key Developments

  • Key players in the global erectile dysfunction (ED) drugs business are expanding their market position by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market positions across the world. A few expansion strategies adopted by players operating in the global erectile dysfunction drugs market are:
    • In December 2020, Glenmark Pharma received the final approval from the U.S. health regulator for Tadalafil tablets, which are used to treat erectile dysfunction and enlarged prostate
    • In June 2020, Launch Medical and GAINSWave announced the resolution of their lawsuit and started working together to market their revolutionary home-use acoustic wave device called The Phoenix for the treatment of erectile dysfunction
  • The report on the global erectile dysfunction (ED) drugs market discusses individual strategies, followed by company profiles of manufacturers of medical device technology products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global market for erectile dysfunction (ED) drugs.

Erectile Dysfunction (ED) Drugs Market Snapshot

Attribute Detail
Market Size Value in 2020 US$ 3.4 Bn
Market Forecast Value in 2028 US$ 2.5 Bn
Growth Rate (CAGR) (3.1)%
Forecast Period 2021-2028
Quantitative Units US$ Bn for Value
Market Analysis It includes cross-segment analysis at the global as well as regional levels. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and a parent industry overview.
Competition Landscape
  • Market Player - Competition Matrix (by tier and size of companies)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug
    • Viagra
    • Cialis
    • Staxyn/Levitra
    • Stendra/Spedra
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Pfizer, Inc.
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Bayer AG
  • Vivus, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • SK Chemicals
  • Meda Pharmaceuticals, Inc.
  • Cristalia Produtos Quimicos Farmaceuticos Ltda. Apricus Biosciences, Inc.
  • Futura Medical plc
  • Other prominent players
Customization Scope Available upon request
Pricing Available upon request

Note: Brackets for CAGR represent negative value.

Frequently Asked Questions

What is the total market worth of erectile dysfunction (ED) drugs market?

The global erectile dysfunction drugs market was worth US$ 3.4 Bn and is projected to reach a value of US$ 2.5 Bn by the end of 2028

What is the anticipated CAGR of the global market for erectile dysfunction drugs in the forecast period?

The erectile dysfunction (ED) drugs market is anticipated to grow at a CAGR of -3.1% during the forecast period

Which region is expected to project the highest market share in the global erectile dysfunction drugs market?

North America accounted for a major share of the global erectile dysfunction (ED) drugs market

What are the key driving factors for the growth of the erectile dysfunction (ED) drugs business?

The market for erectile dysfunction (ED) drugs is being driven by factors such as the adoption of a sedentary lifestyle and the stress that comes with it, the growing geriatric population, and the comorbidity of erectile dysfunction with heart disease and diabetes. 

Who are the key players in the global erectile dysfunction (ED) drugs industry?

Key players in the global erectile dysfunction drugs market include Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, Vivus, Inc., and Teva Pharmaceutical Industries Ltd

1. Preface

    1.1. Market Segmentation

    1.2. Key Research Objectives

    1.3. Research Highlights

2. Assumptions and Research Methodology

    2.1. Secondary Research Methodology

    2.2. Primary Research Methodology

    2.3. Analysis Research Methodology

3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

5. Market Outlook

    5.1. Market Dynamics

        5.1.1. Drivers

        5.1.2. Restraints

        5.1.3. Opportunity

        5.1.4. Opportunity Analysis

        5.1.5. Trends

    5.2. Global Erectile Dysfunction Market Analysis and Forecast, 2018-2028

    5.3. Porter’s Five Forces Analysis

    5.4. Erectile Dysfunction Drugs Market Value Chain Analysis

    5.5. Pipeline Analysis

        5.5.1. Discovery

        5.5.2. Preclinical

        5.5.3. IND (Investigational New Drug)

        5.5.4. Phase I

        5.5.5. Phase I/II

        5.5.6. Phase II

        5.5.7. Phase III

        5.5.8. Pre-registration

    5.6. Global Erectile Dysfunction (ED) Drug Market Outlook

6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Drug

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug, 2018-2028

        6.3.1. Viagra

        6.3.2. Cialis

        6.3.3. Staxyn/Levitra

        6.3.4. Stendra/Spedra

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Drug

7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Distribution Channel, 2018-2028

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Drug, 2018-2028

        9.2.1. Viagra

        9.2.2. Cialis

        9.2.3. Staxyn/Levitra

        9.2.4. Stendra/Spedra

        9.2.5. Others

    9.3. Market Value Forecast, by Distribution Channel, 2018-2028

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Value Forecast, by Country, 2018-2028

        9.4.1. U.S.

        9.4.2. Canada

10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug, 2018-2028

        10.2.1. Viagra

        10.2.2. Cialis

        10.2.3. Staxyn/Levitra

        10.2.4. Stendra/Spedra

        10.2.5. Others

    10.3. Market Value Forecast, by Distribution Channel, 2018-2028

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Market Value Forecast, by Country/Sub-region, 2018-2028

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug, 2018-2028

        11.2.1. Viagra

        11.2.2. Cialis

        11.2.3. Staxyn/Levitra

        11.2.4. Stendra/Spedra

        11.2.5. Others

    11.3. Market Value Forecast, by Distribution Channel, 2018-2028

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Market Value Forecast, by Country/Sub-region, 2018-2028

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug, 2018-2028

        12.2.1. Viagra

        12.2.2. Cialis

        12.2.3. Staxyn/Levitra

        12.2.4. Stendra/Spedra

        12.2.5. Others

    12.3. Market Value Forecast, by Distribution Channel, 2018-2028

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Market Value Forecast, by Country/Sub-region, 2018-2028

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug, 2018-2028

        13.2.1. Viagra

        13.2.2. Cialis

        13.2.3. Staxyn/Levitra

        13.2.4. Stendra/Spedra

        13.2.5. Others

    13.3. Market Value Forecast, by Distribution Channel, 2018-2028

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Market Value Forecast, by Country/Sub-region, 2018-2028

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2020

    14.3. Competitive Business Strategies

    14.4. Company Profiles

        14.4.1. Pfizer, Inc.

            14.4.1.1. Company Overview (HQ, Business Segments, Employee)

            14.4.1.2. Product Portfolio

            14.4.1.3. SWOT Analysis

            14.4.1.4. Strategic Overview

        14.4.2. Dong-A ST Co., Ltd.

            14.4.2.1. Company Overview (HQ, Business Segments, Employee)

            14.4.2.2. Product Portfolio

            14.4.2.3. SWOT Analysis

            14.4.2.4. Strategic Overview

        14.4.3. Eli Lilly and Company

            14.4.3.1. Company Overview (HQ, Business Segments, Employee)

            14.4.3.2. Product Portfolio

            14.4.3.3. SWOT Analysis

            14.4.3.4. Strategic Overview

        14.4.4. Bayer AG

            14.4.4.1. Company Overview (HQ, Business Segments, Employee)

            14.4.4.2. Product Portfolio

            14.4.4.3. SWOT Analysis

            14.4.4.4. Strategic Overview

        14.4.5. VIVUS, INC.

            14.4.5.1. Company Overview (HQ, Business Segments, Employee)

            14.4.5.2. Product Portfolio

            14.4.5.3. SWOT Analysis

            14.4.5.4. Strategic Overview

        14.4.6. SK chemicals

            14.4.6.1. Company Overview (HQ, Business Segments, Employee)

            14.4.6.2. Product Portfolio

            14.4.6.3. SWOT Analysis

            14.4.6.4. Strategic Overview

        14.4.7. Meda Pharmaceuticals, Inc.

            14.4.7.1. Company Overview (HQ, Business Segments, Employee)

            14.4.7.2. Product Portfolio

            14.4.7.3. SWOT Analysis

            14.4.7.4. Strategic Overview

        14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.

            14.4.8.1. Company Overview (HQ, Business Segments, Employee)

            14.4.8.2. Product Portfolio

            14.4.8.3. SWOT Analysis

            14.4.8.4. Strategic Overview

        14.4.9. Apricus Biosciences, Inc.

            14.4.9.1. Company Overview (HQ, Business Segments, Employee)

            14.4.9.2. Product Portfolio

            14.4.9.3. SWOT Analysis

            14.4.9.4. Strategic Overview

        14.4.10. Teva Pharmaceutical Industries Ltd.

            14.4.10.1. Company Overview (HQ, Business Segments, Employee)

            14.4.10.2. Product Portfolio

            14.4.10.3. SWOT Analysis

            14.4.10.4. Strategic Overview

List of Tables

Table 01: Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

Table 02: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

Table 03: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2018-2028

Table 04: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2018-2028

Table 05: North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

Table 06: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

Table 07: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028

Table 08: Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

Table 09: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

Table 10: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028

Table 11: Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

Table 12: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

Table 13: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028

Table 14: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

Table 15: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

Table 16: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028

Table 17: Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

Table 18: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

Table 19: Pfizer, Inc. Products Offered

Table 20: Pfizer, Inc. Recent Developments

Table 21: Dong-A ST Co., Ltd. Products Offered

Table 22: Dong-A ST Co., Ltd. Recent Developments

Table 23: Eli Lilly and Company Products Offered

Table 24: Eli Lilly and Company Recent Developments

Table 25: Bayer AG Products Offered

Table 26: Bayer AG Recent Developments

Table 27: VIVUS, INC. Ltd. Products Offered

Table 28: VIVUS, INC. Recent Developments

Table 29: SK chemicals Products Offered

Table 30: SK chemicals Recent Developments

Table 31: Meda Pharmaceuticals Inc. Products Offered

Table 32: Meda Pharmaceuticals Inc. Recent Developments

Table 33: Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered

Table 34: Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments

Table 35: Apricus Biosciences, Inc. Products Offered

Table 36: Apricus Biosciences, Inc. Recent Developments

Table 37: Teva Pharmaceutical Industries Ltd. Products Offered

List of Figures

Figure 01: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, 2020-2028

Figure 02: Market Value Share, by Drug Class (2020)

Figure 03: Market Value Share, by Distribution Channel (2020)

Figure 04: Market Value Share, by Region (2020)

Figure 05: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

Figure 06: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Viagra, 2020-2028

Figure 07: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Cialis, 2020-2028

Figure 08: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Staxyn/Levitra, 2020-2028

Figure 09: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Stendra/Spedra, 2020-2028

Figure 10: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by others, 2020-2028

Figure 11: Global Erectile Dysfunction (ED) Drug Market Value Share Analysis, by Distribution channel, 2020 and 2028

Figure 12: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2020-2028

Figure 13: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2020-2028

Figure 14: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2020-2028

Figure 15: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Region, 2020 and 2028

Figure 16: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020-2028

Figure 17: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country, 2020 and 2028

Figure 18: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

Figure 19: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 20: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028

Figure 21: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 22: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

Figure 23: Europe Erectile Dysfunction (ED) Drugs Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 24: Asia Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028

Figure 25: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 26: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2020 and 2028

Figure 27: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 28: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028

Figure 29: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 30: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2020 and 2028

Figure 31: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 32: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028

Figure 33: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

Figure 34: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

Figure 35: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

Figure 36: Global Erectile Dysfunction (ED) Drugs Market Share Analysis, by Company (2020)

Figure 37: Pfizer, Inc. Breakdown of Net Sales, by Region, 2020

Figure 38: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2018-2020

Figure 39: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018-2028

Figure 40: Dong-A ST Co., Ltd. Breakdown of Net Sales, by Businesses Segment

Figure 41: Dong-A ST Co., Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020

Figure 42: Dong-A ST Co., Ltd. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018-2028

Figure 43: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020

Figure 44: Eli Lilly and Company R&D Intensity and Sales & Marketing Intensity – Company Level, 2018-2028

Figure 45: Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2020

Figure 46: Eli Lilly and Company Breakdown of Net Sales, (by Endocrinology Level), 2020

Figure 47: Bayer AG Breakdown of Net Sales, by Region, 2020

Figure 48: Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020

Figure 49: Bayer AG R&D Intensity and Net Income (US$ Mn) – Company Level, 2020

Figure 50: VIVUS, INC. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018-2028

Figure 51: VIVUS, INC. Breakdown of Revenue, by Operation (Company Level), 2020

Figure 52: VIVUS, INC. Breakdown of Research and Development Expenses, 2020

Figure 53: SK chemicals Consolidated Balance Sheet (US$ Bn), 2020

Figure 54: SK chemicals Revenue (US$ Bn) and Y-o-Y Growth (%), 2018-2020

Figure 55: SK chemicals R&D Intensity and Net Income (US$ Mn) – Company Level, 2018-2020

Figure 56: Meda Pharmaceuticals Inc. Breakdown of Net Sales, by Region, 2020

Figure 57: Meda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020

Figure 58: Meda Pharmaceuticals Inc. Selling, Medicine &business development and administrative expenses (US$ Mn) – Company Level, 2018-2020

Figure 59: Apricus Biosciences, Inc. Breakdown of Net Sales, by Region, 2020

Figure 60: Apricus Biosciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020

Figure 61: Apricus Biosciences, Inc. R&D and General & administrative (US$ Mn) – Company Level, 2018-2028

Figure 62: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020

Figure 63: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2018-2028

Figure 64: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2020

Figure 65: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2020

Copyright © Transparency Market Research, Inc. All Rights reserved

Erectile Dysfunction (ED) Drugs Market

Schedule a Call